China-based medical instrument producer Peijia Medical has secured CNY700 million (approximately USD100 million) in a Series C funding round from China-focused fund managers Lilly Asia Ventures and Matrix Partners China. Other investors include Far East Horizon’s investment arm Grand Flight Investment and state-owned investment firms China Chengtong Asset Management and SDIC Fund Management. The company, which produces heart-valve disease treatment and neurologic-function recovery tools, will use the new capital to fund further research and development efforts.